Prostamol uno (alcohol extract of the fruits of Serenoa repens) in the treatment of symptomatic benign prostatic hyperplasia;Prostamol uno (alkoholový extrakt z plodov Serenoa repens) v liečbe symptomatickej benígnej prostatickej hyperplázie

Lekarsky Obzor

Volumn 54, Issue 4, 2005, Pages 139-144

  Breza, Ján ^a,d   Kliment, Ján ^a   Valanský, Ladislav ^b   Čápová, Gertrúda ^c  

^a Physics and Informatics   (Slovakia)

^b P J AFÁRIK UNIVERSITY   (Slovakia)

^c Berlin Chemie Slovakia   (Slovakia)

^d Lekárskej Fakulty UK a UN   (Slovakia)

Author keywords

Benign prostatic hyperplasia; Conservative pharmacotherapy

Indexed keywords

PROSTAMOL UNO; SABAL EXTRACT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FRUIT; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; PARAMETER; PENIS ERECTION; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE; SABAL; SYMPTOM;

EID: 23044462530     PISSN: 04574214     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. BREZA, J., KLIMENT, J., BÁRDOŠ, A.: Budúcnost' urológie. Urológia, 10, 2004, s. 8-11.
2. MARBERGER, M., HARKAWAY, R., de la ROSETTE, J.: Optimising the medical management of benign prostatic hyperplasia. Eur Urol, 45, 2004, s. 411-419.
3. DENIS, L., GRIFFITHS, S., KHOURY, A.T.K a kol.: In: Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH). Paris: July 2-5, 1997, s. 439-491.
4. EMBERTON, M., ANDRIOLE, G. L., de la ROSETTE, J., DJAVAN, B., HOEFNER, K., VELA-NAVARRETE, R., NORDLING, J., ROEHRBOR, C., SCHULMAN, C., TEILLAC, P., TUBARO, A., NICKEL, J.C.: Benign prostatic hyperplasia: A progressive disease of aging men. Urology, 61, 2003, s. 267-273.
5. ROEHRBORN, C.G., McNICHOLAS, T.: The management of prostatic obstruction: How to determine the best options? Eur Urol, 2, 2003, Suppl., s. 13-19.
6. KLIMENT, J.: Rastlinné extrakty v liečbe bénignej prostatickej hyperplázie. Med Monitor, 2, 2003, s. 50-53.
7. DREIKORN, K.: The role of phytotherapy in treating lower urinary tract symptoms and benign prostatic hyperplasia. World J Urol, 19, 2002, s. 426-435.
8. CRISTONI, A., Di PIERRO, F., BOMBARDELLI, E.: Botanical derivates for the prostate. Fitoterapia, 71, 2000, s. 521-528.
9. MADERSBACHER, S., ALIVIZATOS, G., NORDLING, J., RIOJA SANZ, C., EMBERTON, M., de la ROSETTE, J.J.: EAU 2004 guidelines on assessment, therapy and follow-up on men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol, 46, 2004, s. 547-554.
10. SCHALKEN, J.A.: The androgen cascade in ageing men: Blessing or curse? Eur Urol, 2, 2003, Suppl., s. 8-12.
11. CARSON, C., III., RITTMASTER, R.: The role of dihydrotestosterone in benign prostatic hyperplasia. Urology, 61, 2003, suppl. 4A, s. 2-7.
12. STEPANOV, V.N., SINIAKOVA, L.A., SARRAZIN, B., RAYNAUD, J.P.: Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: A double-blind comparison of two dosage regimens. Adv Therapy, 16, 1999, č. 5, s. 231-241.
13. BAYNE, C.W., ROSS, M., DONELLY, F., HABIB, F.K.: The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. J Urol, 164, 2000, s. 876-881.
14. CARILLA, E., BRILEY, M., FAURAN, F., SULTAN, Ch., DUVILLIERS, C.: Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem, 20, 1984, s. 521-523.
15. VELA-NAV́ARRETE, R., GARCIA CARDOSO, J.V., BARAT, A., MANZARBEITIA, F., LÓPEZ FARRÉ, A.: BPH and inflammation: Pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol, 44, 2003, s. 549-555.
16. BAYNE, C.W., DONNELLY, F., ROSS, M., HABIB, F.K.: Serenoa repens (Permixon): A 5α-reductase types I and II inhibitor - new evidence in a coculture model of BPH. The Prostate, 40, 1999, s. 232-241.
17. RHODES, L., PRIMKA, R.L., BERMAN, C., VERGULT, G., GABRIEL, M., MALICE, M.P., GIBELIN, B.: Comparison of finasteride (Proscar), a 5 α reductase inhibitor, and various commercial plant extracts in vitro and in vivo 5α reductase inhibition. The Prostate, 22, 1993, s. 43-51.
18. CARRARO, J.C., RAYNAUD, J.P., KOCH, G., CHISHOLM, G.D., di SILVERIO, F., TEILLAC, P., CALAIS DA SILVA, F., CAUQUIL, J., CHOPIN, D.K., HAMDY, F.C., HANUS, M., HAURI, D., KALINTERIS, A., MARENCAK, J., PERIER, A., PERRIN, P.: Comparison of phytotherapy (Permixon) with Finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1 098 patients. The Prostate, 29, 1996, s. 231-240.
19. DEBRUYNE, F., KOCH, G., BOYLE, P., CALAIS da SILVA, F., GILLENWATER, J.G., HAMDY, F.C., PERRIN, P., TEILLAC, P., VELA-NAVARRETE, R., RAYNAUD, J.P.: Comparison of a phytotherapeutic agent (Permixon) with an a-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: A 1-year randomized international study. Eur Urol, 41, 2002, s. 497-507.
20. DEBRUYNE, F., BOYLE, P., CALAIS da SILVA, F., GILLENWATER, J.G., HAMDY, F.C., PERRIN, P., TEILLAC, P., VELA-NAVARRETE, R., RAYNAUD, J. P., SCHULMAN, C.C.: Evaluation of the clinical benefit of Perixon and Tamsulosin in severe BPH patients - PERMAL study subset analysis. Eur Urol, 45, 2004, s. 773-780.
21. BREZA, J., DZURNY, O., BOROWKA, A., HANUS, T, PETRIK, R., BLANE, G., CHADHA-BOREHAM, H.: Efficacy and acceptability of Tadenan (Pygeum africanum Extract) in the treatment of benign prostatic hyperplasia (BPH): A multicentre trial in Central Europe. Current Med Res Opinion, 14, 1998, s. 127-139.
22. LEVIN, R.M., DAS, A.K.: A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol Res, 28, 2000, s. 201-209.